Shub C, Vlietstra R E, Smith H C, Fulton R E, Elveback L R
Mayo Clin Proc. 1981 Mar;56(3):155-60.
To determine whether risk factors or angiographic features could be correlated with progression of coronary artery disease, we independently analyzed serial coronary angiograms in 65 symptomatic patients for progression without knowledge of their respective risk factors. An important design feature of this study was that observer variability of coronary lesion assessment was objectively evaluated and taken into account in defining progression of coronary artery disease. The reproducibility of lesion assessment varied with the severity of stenosis: moderate stenoses had the greatest intraobserver and interobserver variability. At initial study, 337 partial and 68 complete occlusions were identified. Of the 337 partial occlusions at risk of progression, 73 (22%) progressed; 13 (3.2%) of the initial lesions regressed. In the 65 patients with persistent or increasing angina, progression occurred in 51 (78%) over a mean period of 24 months. Apart from the tendency of high-grade stenosis( greater than or equal to 98%) to progress to complete occlusion, no measured clinical, laboratory, or angiographic variable showed any significant effect on progression to coronary artery disease, in this selected group of symptomatic patients these same risk factors did not predict its progression. We believe that (1) and definition of progression should incorporate the factor of observer variability and (2) therapeutic measures designed to influence progression of coronary artery disease should take into account this apparently unpredictable progression.
为了确定危险因素或血管造影特征是否与冠状动脉疾病的进展相关,我们在不了解65例有症状患者各自危险因素的情况下,独立分析了他们的系列冠状动脉造影以观察疾病进展。本研究的一个重要设计特点是,在定义冠状动脉疾病进展时,客观评估并考虑了冠状动脉病变评估中的观察者变异性。病变评估的可重复性随狭窄程度而异:中度狭窄的观察者内和观察者间变异性最大。在初始研究时,共识别出337处部分闭塞和68处完全闭塞。在有进展风险的337处部分闭塞中,73处(22%)发生进展;初始病变中有13处(3.2%)出现消退。在65例持续性或进行性心绞痛患者中,51例(78%)在平均24个月的时间内病情进展。除了高度狭窄(大于或等于98%)有进展为完全闭塞的倾向外,在这组有症状的特定患者中,所测量的任何临床、实验室或血管造影变量均未显示对冠状动脉疾病进展有任何显著影响,这些相同的危险因素也无法预测其进展。我们认为:(1)进展的定义应纳入观察者变异性因素;(2)旨在影响冠状动脉疾病进展的治疗措施应考虑到这种明显不可预测的进展情况。